Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
RSP006-C01 | Pre-coated Anti-IL-2 Antibody Microplate | 1 plate |
RSP006-C02 | Positive Stimulus | 60 μg |
RSP006-C03 | Biotin-Anti-IL-2 Antibody | 50 μL |
RSP006-C04 | Streptavidin-HRP | 50 μL |
RSP006-C05 | Washing Buffer (10×) | 50 mL |
RSP006-C06 | Dilution Buffer (1×) | 50 mL |
RSP006-C07 | AEC Dilution | 25 mL |
RSP006-C08 | AEC Solution A (20×) | 0.8 mL |
RSP006-C09 | AEC Solution B (20×) | 0.8 mL |
RSP006-C10 | AEC Solution C (20×) | 0.8 mL |
This kit is used to detect IL-2 at the cellular level.
It is for research use only.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Your experiment will include 6 simple steps:
a) A monoclonal antibody specific for mouse IL-2 has been pre-coated onto a polyvinylidene difluoride (PVDF)-backed microplate.
b) Appropriately stimulated cells are pipetted into the wells and the microplate is placed into a humidified 37 °C CO2 incubator for a specified period of time.During this incubation period, the immobilized antibody in the immediate vicinity of the secreting cells binds secreted IL-2.
c) After washing away any cells and unbound substances, a biotinylated antibody specific for mouse IL-2 is added to the wells. Following a wash to remove any unbound biotinylated antibody, HRP conjugated to streptavidin is added.
d) Wash the plate and add the Streptavidin-HRP diluted by Dilution Buffer to the plate.
e) Wash the plate and add AEC. A reddish-brown colored precipitate forms and appears as spots at the sites of cytokine localization, with each individual spot representing an individual IL-2 secreting cell.
f) The spots can be counted with an automated ELISpot reader system or manually using a stereomicroscope.
1×10⁵ cells/well Mouse Spleen Cells were stimulated with 6.0 μg/mL Positive Stimulus and cultured at 37℃ and 5%CO2 for 16 h, 265 spots were produced. The following example data is for reference only.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
SHR-1916 | SHR-1916 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours | Details |
STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Skin Appendage; Basal Cell Nevus Syndrome; Keratoacanthoma; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
ITI-1000 | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
NNC-0361-0041 | NNC0361-0041; NNC-0361-0041 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | Details |
XTX-202 | XTX-202 | Phase 2 Clinical | Solid tumours | Details | |
Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
PM-1016 | PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
EQ101 | EQ101 | Phase 2 Clinical | Equillium Inc | Alopecia; Alopecia Areata | Details |
Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Carcinoma, Basal Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
attIL2-T cell therapy | Phase 1 Clinical | MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.